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Abstract 
We have found natural products exhibiting lipolysis-promoting activity in subcutaneous 
adipocytes, which are less sensitive to hormones than visceral adipocytes. The activities and 
a action mechanisms of a novel plant extract of Cirsium oligophyllum (CE) were investigated in 
isolated adipocytes from rat subcutaneous fat, and its fat-reducing effects by peroral ad-
ministration and topical application were evaluated in vivo. CE-induced lipolysis was syner-
gistically enhanced by caffeine, a phosphodiesterase inhibitor, and was reduced by pro-
pranolol, a β adrenergic antagonist. The peroral administration of 10% CE solution to Wistar 
rats for 32 days reduced body weight gain, subcutaneous, and visceral fat weights by 6.6, 
26.2, and 3.0%, respectively, as compared to the control group. By the topical application of 
2% of this extract to rats for 7 days, weight of subcutaneous fat in the treated skin was re-
duced by 23.2%. This fat mass reduction was accompanied by the up-regulation of uncou-
pling protein 1 (UCP), a principal thermogenic mitochondrial molecule related to energy 
dissipating, in subcutaneous fat and UCP3 in skin except for the fat layer. These results in-
dicate that CE promotes lipolysis via a mechanism involving the β adrenergic receptor, and 
affects the body fat mass. This fat reduction may be partially due to UCP up-regulation in the 
skin including subcutaneous fat. This is the first report showing that repeated lipolysis pro-
motion through CE administration may be beneficial for the systematic suppression of body 
fat accumulation or the control of fat distribution in obesity. 
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Introduction 
The excessive accumulation of body fat causes 
problems in terms of health, such as metabolic syn-
drome, as well as esthetics. One of the representative 
measures against excessive body fat accumulation is 
promotion of the lipolysis of neutral lipids accumu-
lated in adipocytes, reducing adipocyte size. 
  The lipolytic reaction in adipocytes is mainly 
explained by the intracellular signaling mechanism 
using cAMP as a second messenger [1, 2, 3]. That is, 
adrenaline and noradrenaline stimulate at least three 
subtypes of β adrenergic receptor (βAR) on the adi-
pocyte cell surface and sequentially induce the acti-
vation of a stimulatory G protein (Gs), increase cAMP 
due to the activation of adenylate cyclase, activate 
cAMP-dependent protein kinase A (PKA), and acti-
vate hormone-sensitive lipase (HSL), resulting in the 
hydrolysis of triglycerides in intracellular lipid drop-
lets. Precise mechanisms involving the modification Int. J. Biol. Sci. 2009, 5 
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of HSL activity or location implicating perilipin, novel 
adipose triglyceride lipase, triglyceride hydrolase, 
and other cofactors, such as CGI-58, have been sug-
gested [4, 5]. 
 β adrenergic agonists, adenylate cyclase acti-
vators, and phosphodiesterase (PDE) inhibitors can 
promote lipolysis; however, obesity reduces adipose 
tissue responsiveness to hormones [6]. Further, sub-
cutaneous fat shows lower lipolytic responses to 
hormones than intra-abdominal (visceral) fat, and the 
above drugs with effects on visceral fat do not always 
have similar, adequate effects on subcutaneous fat [7, 
8]. 
  Uncoupling protein (UCP) is a mitochondrial 
membrane protein that uncouples oxidative phos-
phorylation by bypassing the electrochemical gradi-
ent across the inner membrane from F1-ATPase, 
thereby dissipating energy as heat (thermogenesis) 
[9]. UCP1 is expressed exclusively in brown adipose 
tissue (BAT), which is the major site of regulatory 
thermogenesis of small rodents during cold acclima-
tion, arousal from hibernation, and recovery from 
anesthetic hyperthermia [10]. Since UCP1 is also ac-
tivated during voluntary overfeeding, this isoform is 
believed to be a key molecule for diet- as well as 
cold-induced thermogenesis, and thereby for the 
autonomic control of energy expenditure and total 
body energy balance [11, 12, 13, 14]. UCP2, expressed 
ubiquitously in various tissues, and UCP3, expressed 
abundantly in skeletal muscle and BAT, have been 
suggested to be involved in the regulation of energy 
dissipating [15, 16, 17]. In non-adipose tissue and 
skeletal muscle, we identified UCP2 and UCP3 in the 
human epidermis and dermis, and also UCP1 in the 
epidermis [18]. The expression of skin-UCP was af-
fected by nutritional factors and hormones in in vitro 
experiments; however, the physiological role of 
skin-UCP and regulatory interactions between skin 
components has never been investigated. 
 We have discovered a thistle extract exhibiting a 
remarkable lipolysis-promoting activity in isolated 
subcutaneous adipocytes. In this study, we investi-
gated its mechanism of action, and the in vivo effects 
of its application on the body fat mass and skin-UCP 
expression were evaluated. 
Materials and methods 
Preparation of plant extract 
 In this study, we selected Cirsium oligophyllum as 
a commercial availabile crude drug with lipoly-
sis-promoting activity. Dried plants of Cirsium oligo-
phyllum within Compositae, a type of thistle purchased 
from Tochimoto Tenkaido (Osaka, Japan) were sub-
jected to extraction with a 30% ethanol aqueous solu-
tion at room temperature, followed by heating and 
concentration, and an extract (CE) was obtained. A 
part of the extract was frozen and dried, and the con-
centration of the extracted dry matter of the extract 
was obtained. In this experiment, the extract concen-
tration was expressed as the extracted dry matter 
concentration. For experimental repeatability, we re-
stricted to one species of plant, identified several ac-
tive compounds, and confirmed the stability of its 
quality. 
Animals 
  Male Wistar rats aged 9 weeks (body weight, 
180-220 g) were obtained from Japan SLC, Inc. (Shi-
zuoka, Japan) and maintained at 22±1 C° under a 12-h 
light-dark cycle (lights on from 7:00 AM to 7:00 PM). 
The rats were fed laboratory chow, CE-2 obtained 
from CLEA Japan, Inc. (Tokyo, Japan), and allowed ad 
libitum  access to water for a week to stabilize the 
metabolic conditions.  
We were certain that all applicable institutional 
and governmental regulations concerning the ethical 
use of animals were followed during this research. All 
animal experiments were conducted in the Experi-
mental Animal Facility of Kao Tochigi Institute. The 
Animal Care Committee of Kao Tochigi Institute ap-
proved the present study. All experiments strictly 
followed the guidelines of that committee.  
Isolation of adipocytes 
  Isolated adipocytes were prepared from the 
abdominal-inguinal subcutaneous fat pads of three 
Wistar male rats aged 9 weeks and weighing about 
180-220 g, according to the method reported by Rod-
bell [19]. Briefly, the excised adipose tissue was cut 
into small pieces using ophthalmologic scissors, sus-
pended and washed with Hank’s buffer containing 
2% bovine serum albumin fraction V, and digested 
with collagenase Type I in the presence of 1mg/ml 
glucose for about 60 minutes at 37°C. The digested 
tissue was filtered through a nylon mesh (mesh size: 
40 μm), and floating cells were collected and gently 
rinsed 3 times with Hank’s buffer, and suspended in 
the same buffer. 
Treatment of isolated adipocytes 
  The isolated adipocyte suspension was incu-
bated with various concentrations of NA, CE, pro-
pranorol, as an β adrenergic antagonist, or caffeine, as 
a PDE inhibitor, in Hank’s buffer at 37°C for 2 hours. 
The glycerol released into the buffer after incubation 
was measured using the enzyme method [20]. Briefly, 
the buffer after stimulation was mixed with glyc-
erol-detecting solution and absorbance was measured Int. J. Biol. Sci. 2009, 5 
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at 480 nm. The composition of the glycerol-detecting 
solution was 2.7 mmol/l p-chlorophenol, 0.04% Triton 
X-100, 2 mmol/l magnesium sulfate, 2 mmol/l ATP, 
0.05 mmol/l 4-amino antipiline, 1 mmol/l EDTA, 0.5 
U glycerokinase, 4 U glycerol-3-phosphate oxidase 
and 2 U peroxidase. The quantified glycerol concen-
tration was normalized by the number of isolated 
adipocytes, calculated using a hematocytometer. All 
determined data are presented as the mean ± S.E.M. of 
triplicate incubation tubes for each condition.  
Peroral administration 
 Male Wistar rats were divided into three groups 
(8 rats in each group) to standardized the body weight 
among the groups, and they orally received water 
(control group) or 3 or 10% CE aqueous solution (0.5 
ml) twice daily by gavage. Animals were maintained 
on the treatment for 32 days.  
Topical application  
 Male Wistar rats were divided into six groups (8 
rats in each group) to standardized the body weight 
among groups. The hair on their back was shaved 
once every 2-3 days, and water (control group) or 0.05, 
0.2, 0.5, 1, or 2% CE (0.2 ml) was applied to the shaved 
area (about 5 x 5 cm) twice daily. The animals were 
maintained on the treatment for 7 days. 
Food intake, body weight, adipose tissue weight, 
and tissue samples 
Food intake represented the total weight of 
consumed chow per animal. The body weight was 
measured weekly throughout the study. After the 
application, adipose tissue comprising subcutaneous 
and intra-abdominal (visceral) fat was dissected from 
each animal according to defined anatomical land-
marks and weighed. Dissected portions were the in-
terscapular fat pad of the back as subcutaneous fat, as 
well as epididymal, retroperitoneal, and perirenal 
adipose tissue as visceral fat. 
For RNA analysis, whole skin, excluding subcu-
taneous fat, was obtained from the back, and cutane-
ous muscle was separated. This superficial layer of 
skin, consisting of the epidermis and dermis, without 
subcutaneous components was used as the “superfi-
cial skin” sample in this study. White adipose tissue 
(WAT) of the superficial area of the interscapular fat 
pad was used as the subcutaneous WAT. BAT from 
the deep brown area of the interscapular fat pad was 
used as a positive control tissue expressing UCP. 
RNA extraction and RT-PCR analysis 
Total RNA was extracted with gua-
nidine-isothiocyanate using Isogen with proteinase K 
and DNase I treatment according to the manufac-
turer’s instructions. The mRNA of each UCP subtype 
was analyzed with the reverse transcriptase poly-
merase chain reaction (RT-PCR). Briefly, cDNA was 
synthesized from total RNA (5-20ng) using TaqMan 
Reverse Transcription Reagents, and quantified by 
real-time PCR with a TaqMan PCR kit using an ABI 
Prism 7700 (Applied Biosystems Japan, Tokyo, Japan) 
according to the manufacturer’s instructions. Se-
quences (5’ to 3’ end) of primer sets and fluores-
cence-labeled probe for real-time PCR were 
TGCACCACCAACTGCTTAGC, GGCATGGACTGT 
GGTCATGA and TCCATGACAACTTTGGCATCGT 
GGAA (front primer, reverse primer and probe, re-
spectively) for rat GAPDH(GenBank No.NM017008), 
ATCATCACCTTCCCGCTGG, CCTGGCCTTCACCT 
TGGA and CACCGCCAAAGTCCGCCTTCA for rat 
UCP1 (No.X03894), CCTCCTGAAAGCCAACCTCA, 
CCTTTGGGGCAGGCTTCT and ACAGACGACCTC 
CCTTGCCACTTCACTTCT for rat UCP2 
(No.AB006613), GGGCCCCACAGCCTTCTAC, 
TCACGTTCCAGGATCCCAGA and 
AAAGGATTCATGCCCTCCTTTCTGCG for rat 
UCP3 (No.U92069).  
Chemicals 
    NA, propranolol, and caffeine were ob-
tained from Wako Pure Chemical Industries (Osaka, 
Japan). Bovine serum albumin fraction V purchased 
from Sigma (MO, USA), and collagenase type I from 
Worthington Biochemical (NJ, USA), Isogen from 
Nippon Gene (Tokyo, Japan), proteinase K and DNase 
I treatment from Qiagen (Hilden, Germany), TaqMan 
Reverse Transcription Reagents and TaqMan PCR kit 
from Applied Biosystems Japan (Tokyo, Japan) were 
used. 
Statistical analysis 
All determined data are presented as the mean ± 
S.E.M. of each condition. The data were analyzed by 
ANOVA followed by the Bonferroni method for mul-
tiple comparisons between pairs. Each experiment 
was repeated at least three times with similar results. 
Results 
Lipolysis-promoting activity in adipocytes 
  The lipolysis-promoting activity of CE in iso-
lated subcutaneous adipocytes was compared to NA. 
As can be seen in Fig. 1, CE showed marked lipoly-
sis-promoting activity, and its EC50 was about 35 
μg/ml. The maximum response to CE was the same as 
that to NA. The synergism of CE and other pharma-
cological agents is shown in Fig. 2. Caffeine synergis-
tically enhanced CE-induced lipolysis; the maximum 
response to this combination was the same as that to Int. J. Biol. Sci. 2009, 5 
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CE alone, but the EC50 of the former was about 4.2 
μg/ml, 1/10-fold that of the latter. Co-treatment of CE 
with NA barely exerted an additional effect. Pro-
pranolol markedly reduced the lipolysis-promoting 
activity of CE (Fig. 3), and the degree of reduction 
depended on the concentration of propranolol added 
(data not shown).  
 
 
 
 
Fig. 1. Promotion of lipolysis by CE and NA. Adipocytes 
were isolated from subcutaneous fat pads and treated with 
CE or NA for 120 min, and released glycerol was measured. 
Each value represents the mean ± S.E.M. of three incubation 
tubes for each condition. 
 
 
 
 
 
 
 
Fig. 2. Promotion of lipolysis by CE with caffeine or NA. 
Adipocytes were isolated from subcutaneous fat pads and 
treated with CE and caffeine (0.1 mM) or NA (0.1μg/ml) for 
120 min, and released glycerol was measured. Short dashed 
line represents level of Caf or NA treatment. Each value 
represents the mean ± S.E.M. of three incubation tubes for 
each condition. 
 
Fig. 3. Promotion of lipolysis by CE with propranolol. 
Adipocytes were isolated from subcutaneous fat pads and 
treated with CE and propranolol (0.1 μM) for 120 min, and 
released glycerol was measured. Each value represents the 
mean ± S.E.M. of three incubation tubes for each condition. 
Changes of body weight and fat mass by peroral 
administration 
 As CE exhibited a transient lipolysis-promoting 
activity, the effects of the daily oral administration of 
3 or 10% CE aqueous solution on the body fat were 
evaluated in vivo. As Fig. 4 shows, body weight gain 
was gradually reduced, and the final value after ad-
ministration for 32 days was significantly lower in the 
CE groups than in the control group. While food in-
take during the administration period did not differ 
among the groups (Table. 1), the final body weight 
was reduced by 6.6% on average in the group given 
10% CE, and the degree of reduction depended on the 
CE concentration. Both the subcutaneous and visceral 
fat weights were significantly lower in the CE than in 
the control group. Mean reduction rates were 26.2% 
for subcutaneous fat and 3.0% for visceral fat, con-
firming the body fat-reducing effects of the peroral 
administration of this extract. 
 
Fig. 4. Body weight changes by the peroral administration 
of CE. Wistar rats perorally received water (control group) 
or 3 or 10% CE solution twice daily for 32 days. Each value 
represents the mean ± S.E.M. of eight animals for each 
group. *: P<0.05, compared with the value of the control 
group. Int. J. Biol. Sci. 2009, 5 
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Changes in body fat mass and UCP expression on 
topical application 
 The effects of a daily topical application of 0.05, 
0.2, 0.5, 1, or 2% CE aqueous solution to the skin on 
body fat were evaluated. As shown in Table 2, during 
the topical application period for 7 days, neither the 
food intake nor final body weight differed among 
groups. However, the subcutaneous fat weight on the 
back, the area of agent application, was significantly 
lower in the groups given CE at concentrations ≥ 0.5% 
as compared to the control group; the 2% CE group 
showed a mean reduction of 23.2%. The extent of re-
duction depended on the CE concentration. The vis-
ceral fat weight in the CE groups was not significantly 
reduced.  
  UCP expression in subcutaneous fat and the 
superficial skin of the treated area were compared in 
the control and 0.5% CE group. In subcutaneous WAT 
(Fig. 5a), UCP1 was barely expressed in the control 
group, but the level was significantly increased 
(1.5-fold compared to the control group) in the CE 
group to half of that of BAT in the control group. 
UCP1 expression in BAT was slightly up-regulated 
(1.3-fold). However, UCP2 and UCP3 mRNAs in 
WAT and BAT were not altered by CE application. In 
contrast to adipose tissue, only UCP3 was markedly 
increased (2.6-fold) by CE application in the superfi-
cial skin (Fig. 5b). No significant expression of UCP1 
was observed, and UCP1 and UCP2 were not 
up-regulated in this tissue.  
 
 
 
 
 
Table 1. Changes in food intake, body weight, and adipose tissue weight by the peroral administration of CE. Wistar rats 
perorally received water (control group) or 3 or 10% CE solution twice daily for 32 days. Each value represents the mean ± 
S.E.M. of eight animals for each group. *: P<0.05, compared with the value of the control. 
  Total Food Intake (g)    Final Body Weight (g)    Subcutaneous Fat Weight (g)  Visceral Fat Weight (g)  
Concentration (%) Mean  SEM Relative Value Mean  SEM Relative Value Mean  SEM  Relative Value Mean  SEM  Relative Value
0 (Control)  847.4  33.3  100.0    389.8  6.4  100.0    8.000  0.440  100.0    8.30  0.35  100.0   
3 850.1  33.0  100.3    372.3  7.7  95.5  *  7.100  0.350  88.8  *  8.18  0.36  98.6  * 
10 829.8  34.1  97.9    364.0  4.4  93.4  *  5.900  0.370  73.8  *  8.05  0.40  97.0  * 
 
 
 
 
 
 
Table 2. Changes in food intake, body weight, and adipose tissue weight by the topical application of CE. Wistar rats were 
externally applied with water (control group) or CE solution twice daily for 7 days. Each value represents the mean ± S.E.M. 
of eight animals for each group. *: P<0.05, compared with the value of the control. 
  Total Food Intake (g)    Final Body Weight (g)    Subcutaneous Fat Weight (g)   Visceral Fat Weight (g) 
Conc (%)  Mean  SEM  Relative %     Mean  SEM Relative %     Mean SEM  Relative %     Mean  SEM  Relative % 
0  (Control)  190.2 20.5 100.0    161.0 9.1  100.0    0.322 0.076 100.0    1.031 0.108 100.0 
0.05  189.1 22.3 99.4    160.7 7.5  99.8    0.314 0.034 97.5    1.031 0.180 100.0 
0.2  192.4 18.9 101.2    162.5 5.8  100.9    0.261 0.040 81.3    1.018 0.193 98.8 
0.5  185.8 20.1 97.7    164.6 4.6  102.2    0.257 0.018 80.0  *  0.997 0.155 96.8 
1  191.9 22.0 100.9    161.8 8.7  100.5    0.241 0.009 75.0  *  1.005 0.129 97.5 
2  190.7 17.8 100.3    164.2 2.6  102.0    0.247 0.019 76.8  *  0.967 0.155 93.8 
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Fig. 5. Changes in UCP expression in subcutaneous fat (a) and the superficial skin (b) by the topical application of CE. Wistar 
rats were externally applied with water (control group) or 0.5% CE solution twice daily for 7 days. WAT represents white 
adipose tissue of subcutaneous fat, compared to BAT. Each value represents the mean ± S.E.M. of eight animals for each 
group relative to the control group. *: P<0.05, compared with the value of the control group. 
 
 
Discussion 
  The promotion of lipolysis in adipocytes is one 
of the main strategies to prevent fat accumulation; 
however, obesity-related diabetes was found to be 
accompanied by catecholamine resistance, showing 
low-level metabolic responsiveness [6, 21, 22]. Fur-
ther, there have been many reports showing regional 
differences in adipose metabolism, including respon-
siveness to dietary treatments or exercise and lipoly-
sis-promoting hormones [23, 24, 25, 26]. Since 
enlarged adipocytes in obesity and subcutaneous 
adipocytes were less sensitive to lipolytic hormones, 
our hypothesis was that substances exhibiting a 
lipolysis-promoting activity in enlarged subcutaneous 
adipocytes could promote in vivo fat mobilization.  
We selected CE as a natural product with 
marked lipolysis-promoting effects in isolated sub-
cutaneous adipocytes, and investigated its in vitro 
activity and in vivo efficacy. Experiments using the 
PDE inhibitor and β antagonist showed that CE could 
directly promote adipose lipolysis, and strongly sug-
gested that this activity is mediated mainly by βAR, 
similarly to the β agonist. We investigated Cirsium 
oligophyllum, a species of thistle, which has long been 
eaten as a vegetable in a particular area of Asia. 
However, it has never been clarified whether this 
plant exhibits some pharmacological effects or con-
tains compounds modulating fat metabolism or adi-
pose function. We identified several alkaloid deriva-
tives, but further investigation is necessary to confirm 
precise active compounds within this plant.  
  After confirming transient lipolysis-promoting 
activity  in vivo by peroral administration and the 
transdermal absorption of CE (data not shown), we 
investigated whether the repeated stimulation of 
lipolysis by CE can mobilize body fat. The peroral 
administration of CE inhibited body weight gain and 
fat accumulation, and its topical application also 
markedly reduced subcutaneous fat accompanying no 
change in the visceral fat weight. The efficacy of 
peroral administration suggested dietary applicability Int. J. Biol. Sci. 2009, 5 
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of CE to reduce the fat mass systemically. The fat re-
duction may have been due to the accumulation of 
effects promoting lipolysis; however, body weight 
reduction was possibly due to enhanced energy con-
sumption, since CE intake showed no toxicity, such as 
a decrease in food intake or diarrhea. Previous studies 
have reported a reduction of body fat after the con-
secutive intake of CL316243, a β3 adrenergic agonist, 
in mice [27, 28, 29, 30], and after similar intake of 
methylxantines [31, 32, 33]. Regarding the efficacy of 
β3 agonist treatment, not only transient lipolysis 
promotion, but also the role of UCP activity in energy 
dissipating was strongly suggested. From this view-
point, Inokuma et al. [34] provided evidence that UCP 
activation is indispensable for fat reduction by β 
adrenergic stimulation using UCP1-knockout mice. 
Direct evidence for changes in energy balance brought 
about by CE administration has to be generated as the 
next step. 
  Contrary to a previous study [26], the effect on 
the fat mass of CE administration was larger in sub-
cutaneous than visceral fat. It is possible that the 
topically applied region showed a stronger response 
portion to CE; however, further examinations in obese 
model rats or obese humans are necessary.  
 The efficacy of topical application suggested the 
applicability of CE to nutra-ceutical external agents 
that can alter regional fat accumulation. Since signifi-
cant fat reduction was restricted to the applied region, 
being less effective for visceral and subcutaneous fat 
in other separated regions (data not shown), it was 
revealed that CE can be transdermaly absorbed and it 
directly affects the metabolism of subcutaneous fat. 
Interestingly, the repeated application of CE mark-
edly up-regulated UCP3 in the superficial skin, and 
significantly increased UCP1 mRNA in subcutaneous 
WAT and BAT, suggesting that regional subcutane-
ous fat reduction was induced by CE due to not only 
transient lipolysis promotion but also the activation of 
UCP.  
  There have been few studies on the efficacy of 
the external application of agents on fat mobilization. 
Topical fat reduction by the external application of a 
preparation containing aminophylline, a PDE inhibi-
tor, was reported [35]; however, there are no reports 
of fat reduction due to external β agonistic application 
and no discussion on UCP activation in skin including 
subcutaneous fat. Contrary to our previous report on 
human skin [18], the superficial skin of rats showed 
no expression of UCP1 but expressed UCP3, which 
was up-regulated by β stimulation on CE treatment, 
suggesting that functional subtypes of skin-UCP dif-
fer between species, and possibly exhibit some 
physiological functions responding to hormonal sig-
nals. In the case of skeletal muscle and myocytes, the 
up-regulation of UCP3 caused by catecholamines, 
fasting, or exercise was reported [36]. Since interac-
tions between the metabolic pathway and the tran-
scriptional regulation of skin components have not 
been revealed, these need to be elucidated in detail.  
 Another possible mechanism of the action of CE 
involves the activation of the autonomic nervous sys-
tem. Lipolysis and UCP activation are also controlled 
by the autonomic nervous system, and olfactory 
stimulation by fruit or spices can stimulate nerve ac-
tivity and promote lipolysis [37]. Whether or not the 
in vivo efficacy of CE administration involves the ac-
tivity of the autonomic nervoous system innervating 
adipose tissue or the skin also remains to be deter-
mined. 
  This study showed that CE could transiently 
promote lipolysis via a mechanism involving βAR, 
similar to β agonist, and that the chronic administra-
tion of this agent reduced the body fat mass systemi-
cally or regionally, accompanied by the up-regulation 
of skin-UCP. This is the first report showing the in 
vivo efficacy of a repeatedly applied β agonist to 
promote lipolysis leading to fat reduction or the 
modification of fat distribution and expression of 
skin-UCP. These results suggested that dietary and 
external applications could be beneficial methods for 
systematic fat reduction or the control of fat distribu-
tion, and that synergistic enhancement of efficacy 
could be expected in combination with other active 
ingredients. Further studies are necessary to confirm 
the action mechanism of this material, involving al-
teration of the energy balance, and to evaluate its 
possible application to health promotion and esthet-
ics. 
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